Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447330 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
A Phase 2 study of Neoplasm Metastasis and Esophageal Neoplasms, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00447330: Completed Phase 2 study of Neoplasm Metastasis and Esophageal Neoplasms, sponsored by Duke University.
NCT00447330 is a Phase 2 study of Neoplasm Metastasis and Esophageal Neoplasms that has completed, run by Duke University. The registered enrollment target is 60 participants, below the 414-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00447330, a Phase 2 study of Neoplasm Metastasis and Esophageal Neoplasms, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
Primary Outcome
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression.
Conditions Studied
Interventions
- DRUG capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Study Locations (2)
North Carolina
- Duke University Medical Center - Durham
- University of Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-02 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT00447330 record still lists
NCT00447330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 414-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (86% lower).
The record links to 3 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 1 intervention - of which capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) is the first listed.
NCT00447330 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00447330 about?
NCT00447330 is a clinical study titled "Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma". The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
What is the current status of trial NCT00447330?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-02. Estimated completion is 2014-07.
What conditions does trial NCT00447330 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Esophageal Neoplasms, Stomach Neoplasms.
What interventions are being tested in trial NCT00447330?
The interventions under investigation include: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) (DRUG).
Who is sponsoring clinical trial NCT00447330?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00447330 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00447330's enrollment target sits among peer trials
60 28th of 41 higher than 13 of 41 other Neoplasm Metastasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasm Metastasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
9-ING-41 in Patients with Advanced Cancers
ACTIVE NOT RECRUITING · Phase 2
-
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
ACTIVE NOT RECRUITING · Phase 2
-
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia